HemaSphere (Jun 2022)
P372: DISMAL OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER FAILURE OF BOTH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB
- W. Macaron,
- E. Jabbour,
- M. Konopleva,
- F. Ravandi,
- N. Jain,
- G. Issa,
- T. Kadia,
- K. Sasaki,
- P. Kebriaei,
- M. Yilmaz,
- P. Thompson,
- K. Takahashi,
- H. Abbas,
- W. Wierda,
- R. Garris,
- H. Kantarjian,
- N. Short
Affiliations
- W. Macaron
- 1 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, United States of America
- E. Jabbour
- 1 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, United States of America
- M. Konopleva
- 1 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, United States of America
- F. Ravandi
- 1 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, United States of America
- N. Jain
- 1 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, United States of America
- G. Issa
- 1 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, United States of America
- T. Kadia
- 1 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, United States of America
- K. Sasaki
- 1 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, United States of America
- P. Kebriaei
- 1 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, United States of America
- M. Yilmaz
- 1 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, United States of America
- P. Thompson
- 1 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, United States of America
- K. Takahashi
- 1 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, United States of America
- H. Abbas
- 1 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, United States of America
- W. Wierda
- 1 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, United States of America
- R. Garris
- 1 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, United States of America
- H. Kantarjian
- 1 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, United States of America
- N. Short
- 1 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, United States of America
- DOI
- https://doi.org/10.1097/01.HS9.0000844376.80277.de
- Journal volume & issue
-
Vol. 6
pp. 272 – 273
Abstract
No abstracts available.